ES2192585T3 - Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion. - Google Patents
Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion.Info
- Publication number
- ES2192585T3 ES2192585T3 ES95940409T ES95940409T ES2192585T3 ES 2192585 T3 ES2192585 T3 ES 2192585T3 ES 95940409 T ES95940409 T ES 95940409T ES 95940409 T ES95940409 T ES 95940409T ES 2192585 T3 ES2192585 T3 ES 2192585T3
- Authority
- ES
- Spain
- Prior art keywords
- interleucine
- superagonists
- antagonists
- superantagonists
- location
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/141—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
Abstract
SE SABE QUE LOS LIGANDOS DEL GRUPO DE CITOQUINAS SIMILAR A LA INTERLEUCINA 6(IL-6), QUE ES ONCOSTATINA-M(OSM), EL FACTOR INHIBITORIO DE LA LEUCEMIA (LIF), EL FACTOR NEUROTROFICO CILIAR (CNTF) E LA INTERLEUCINA II (IL-II), INDUCEN LA FORMACION DE UN COMPLEJO RECEPTOR DEL CUAL FORMA PARTE LA MOLECULA DE MEMBRANA GP 130. LA PRESENTE INVENCION SE REFIERE A UNA METODOLOGIA PARA LA SELECCION DE SUPERAGONISTAS, ANTAGONISTAS Y SUPERANTAGONISTAS DE LA INTERLEUCINA-6 HUMANA QUE COMPRENDE LAS SIGUIENTES OPERACIONES: COMPARAR LA SECUENCIA DE AMINOACIDO DE LA COLONIA DE GRANULOCITOS BOVINOS QUE ESTIMULAN EL FACTOR (BG-CSF) CON LA SECUENCIA DE DICHA HORMONA, Y EN BASE A LA COMPARACION ANTERIORMENTE MENCIONADA, FORMULAR UN MODELO TRIDIMENSIONAL DE DICHA HORMONA, EL CUAL PERMITE LA IDENTIFICACION DE LOS RESIDUOS QUE FORMAN EL EMPLAZAMIENTO DE LA INTERACCION CON EL RECEPTOR ESPECIFICO (EMPLAZAMIENTO 1) Y ESOS QUE CONSTITUYEN EL EMPLAZAMIENTO DE LA INTERACCION CON EL GP 130 (EMPLAZAMIENTO 2) RESPECTIVAMENTE.LA INVENCION PERMITE LA IDENTIFICACION DE ESTOS EMPLAZAMIENTOS EN INTERLEUCINA-6 HUMANA Y EL AISLAMIENTO DE LAS VARIANTES QUE TIENEN, CON RESPECTO A LA HORMONA DE TIPO SALVAJE, UNA MAYOR AFINIDAD PARA EL RECEPTOR ESPECIFICO (SUPERAGONISTAS Y SUPERANTAGONISTAS) O AFINIDAD PARA EL GP 130 REDUCIDO O ABOLIDO (ANTAGONISTAS Y ANTAGONISTAS). LA FIGURA DEMUESTRA UN ESQUEMA QUE ILUSTRA LA METODOLOGIA APLICADA PARA IDENTIFICAR EL EMPLAZAMIENTO 1 Y EL EMPLAZAMIENTO 2 EN EL CASO DE LA INTERLEUCINA-6 HUMANA. LA INVENCION TAMBIEN DESCRIBE LA OBTENCION DE SUPERAGONISTAS Y SUPERANTAGONISTAS ESPECIFICAS DE LA INTERLEUCINA-6 Y EL USO DE SUPERANTAGONISTAS COMO INHIBIDORES DE DOSIS BAJA DEL CRECIMIENTO DE CELULAS DE MIELOMAS HUMANOS DEPENDIENTES DE LA INTERLEUCINA-6 DE TIPO SALAVAJE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM940805A IT1274782B (it) | 1994-12-14 | 1994-12-14 | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2192585T3 true ES2192585T3 (es) | 2003-10-16 |
Family
ID=11402859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES95940409T Expired - Lifetime ES2192585T3 (es) | 1994-12-14 | 1995-12-13 | Superagonistas y antagonistas de la h il-6 y metodo de modelado tridimensional para su seleccion. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US5849283A (es) |
| EP (1) | EP0745094B1 (es) |
| JP (2) | JP3206919B2 (es) |
| CN (1) | CN1070866C (es) |
| AT (1) | ATE234864T1 (es) |
| AU (1) | AU702783B2 (es) |
| CA (1) | CA2177838A1 (es) |
| DE (1) | DE69529973T2 (es) |
| DK (1) | DK0745094T3 (es) |
| ES (1) | ES2192585T3 (es) |
| IT (1) | IT1274782B (es) |
| PT (1) | PT745094E (es) |
| WO (1) | WO1996018648A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997016202A1 (en) * | 1995-10-27 | 1997-05-09 | Amrad Operations Pty. Ltd. | Cytokines and their use in treatment and/or prophylaxis of breast cancer |
| JP3824173B2 (ja) * | 1995-11-07 | 2006-09-20 | 株式会社カネカ | 自己抗原 |
| IT1285790B1 (it) | 1996-09-24 | 1998-06-24 | Angeletti P Ist Richerche Bio | Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o |
| AUPO439396A0 (en) | 1996-12-24 | 1997-01-23 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment and prophylaxis |
| GB9702944D0 (en) * | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
| CA2237915A1 (en) * | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| WO2000001404A1 (en) | 1998-07-06 | 2000-01-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for $i(in vitro) fertilization |
| JP4799516B2 (ja) * | 1998-08-24 | 2011-10-26 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤 |
| ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
| US6541244B1 (en) * | 1999-06-07 | 2003-04-01 | Cedars-Sinai Medical Center | Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans |
| WO2001016166A2 (en) * | 1999-08-27 | 2001-03-08 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| US7247618B2 (en) * | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
| RU2318829C2 (ru) * | 2001-11-14 | 2008-03-10 | Сентокор, Инк. | Антитела против il-6, композиции, способы и применение |
| US20060165683A1 (en) | 2001-12-05 | 2006-07-27 | Gerard Karsenty | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| CA2516945A1 (en) | 2003-02-24 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for spinal cord injury comprising interleukin-6 antagonist |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| RU2554942C2 (ru) | 2003-10-17 | 2015-07-10 | Тугаи Сейяку Кабусики Кайся | Терапевтический агент для мезотелиомы |
| US20050100550A1 (en) * | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| PA8672101A1 (es) * | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
| US8945558B2 (en) | 2005-10-21 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor |
| AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
| EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
| EP2025346B1 (en) | 2006-04-07 | 2016-08-10 | Osaka University | Muscle regeneration promoter |
| KR101508019B1 (ko) | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| TWI528973B (zh) | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
| US8188235B2 (en) * | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| EP2578233B1 (en) | 2010-05-28 | 2017-04-26 | National Cancer Center | Therapeutic agent for pancreatic cancer |
| SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
| EP2787007A3 (en) | 2010-11-08 | 2015-03-11 | F. Hoffmann-La Roche AG | Subcutaneously administered ANTI-IL-6 receptor antibody |
| WO2014200018A1 (ja) | 2013-06-11 | 2014-12-18 | 独立行政法人 国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| TWI873632B (zh) | 2015-02-27 | 2025-02-21 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| WO2020213665A1 (ja) | 2019-04-17 | 2020-10-22 | 国立大学法人広島大学 | Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2147466A1 (en) * | 1992-10-20 | 1994-04-28 | Just P. J. Brakenhoff | Interleukin-6 receptor antagonists |
| IT1263022B (it) * | 1992-11-06 | 1996-07-23 | Angeletti P Ist Richerche Bio | Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica. |
-
1994
- 1994-12-14 IT ITRM940805A patent/IT1274782B/it active IP Right Grant
-
1995
- 1995-12-13 WO PCT/IT1995/000216 patent/WO1996018648A1/en not_active Ceased
- 1995-12-13 CA CA002177838A patent/CA2177838A1/en not_active Abandoned
- 1995-12-13 DE DE69529973T patent/DE69529973T2/de not_active Expired - Fee Related
- 1995-12-13 ES ES95940409T patent/ES2192585T3/es not_active Expired - Lifetime
- 1995-12-13 AT AT95940409T patent/ATE234864T1/de not_active IP Right Cessation
- 1995-12-13 PT PT95940409T patent/PT745094E/pt unknown
- 1995-12-13 DK DK95940409T patent/DK0745094T3/da active
- 1995-12-13 US US08/693,182 patent/US5849283A/en not_active Expired - Fee Related
- 1995-12-13 EP EP95940409A patent/EP0745094B1/en not_active Expired - Lifetime
- 1995-12-13 CN CN95191575A patent/CN1070866C/zh not_active Expired - Fee Related
- 1995-12-13 JP JP51856296A patent/JP3206919B2/ja not_active Expired - Fee Related
- 1995-12-13 AU AU41871/96A patent/AU702783B2/en not_active Ceased
-
1998
- 1998-01-16 US US09/008,482 patent/US5914106A/en not_active Expired - Fee Related
-
2001
- 2001-04-24 JP JP2001125516A patent/JP3286310B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU702783B2 (en) | 1999-03-04 |
| DK0745094T3 (da) | 2003-06-10 |
| EP0745094A1 (en) | 1996-12-04 |
| CN1070866C (zh) | 2001-09-12 |
| US5849283A (en) | 1998-12-15 |
| AU4187196A (en) | 1996-07-03 |
| CN1140456A (zh) | 1997-01-15 |
| HK1011032A1 (en) | 1999-07-02 |
| CA2177838A1 (en) | 1996-06-15 |
| JPH09502460A (ja) | 1997-03-11 |
| WO1996018648A1 (en) | 1996-06-20 |
| DE69529973T2 (de) | 2003-12-04 |
| JP3206919B2 (ja) | 2001-09-10 |
| JP3286310B2 (ja) | 2002-05-27 |
| JP2001354698A (ja) | 2001-12-25 |
| PT745094E (pt) | 2003-07-31 |
| ITRM940805A1 (it) | 1996-06-14 |
| ATE234864T1 (de) | 2003-04-15 |
| EP0745094B1 (en) | 2003-03-19 |
| IT1274782B (it) | 1997-07-24 |
| DE69529973D1 (de) | 2003-04-24 |
| ITRM940805A0 (it) | 1994-12-14 |
| US5914106A (en) | 1999-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT745094E (pt) | Superagonistas e antagonistas da il-6 humana e metodo para a sua seleccao | |
| ES2177789T3 (es) | Peptidos antagonistas de lhrh. | |
| DE69233772D1 (de) | T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe) | |
| ES2056908T3 (es) | Analogos nonapeptidos y decapeptidos de la lhrh utiles como antagonistas de la lhrh. | |
| CY1107556T1 (el) | Συνθεσεις αναλογων g-csf και μεθοδοι | |
| EP1680443A4 (en) | PEPTIDES WITH STABILIZED ALPHA HELIX AND ITS USES | |
| ES2170172T3 (es) | Procedimiento y composiciones para inhibir las proteina quinasas. | |
| DK149896C (da) | Analogifremgangsmaade til fremstilling af lrf-analoge nona- eller decapeptidamider eller ikke-toksiske salte deraf | |
| ES535842A0 (es) | Un procedimiento para preparar octapeptidos lineales | |
| ES2059354T3 (es) | Un metodo para producir un polipeptido. | |
| MX9604047A (es) | Secrecion aumentada de polipeptidos. | |
| ATE306549T1 (de) | C-c ckr-1, ein c-c chemokin rezeptor | |
| MX9203519A (es) | Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos. | |
| YU46223B (sh) | Postupak za dobivanje 1-/4-aminofenil/-4-metil-7,8-metilendioksi-3,4-dihid ro-5h-2,3-benzodiazepina | |
| BG104267A (en) | Aminoterminally incised rantes as haemokin antagonists | |
| NO165804C (no) | Veksthormon-frigjoerende peptider og anvendelse derav. | |
| ES2090018T3 (es) | Clon de adn de trombomodulina humana. | |
| SE8403630L (sv) | Humana proteiner | |
| ES2144524T3 (es) | Metodologia para seleccionar superagonistas, antagonistas y superantagonistas de la interleuquina 6. | |
| ES512533A0 (es) | Un procedimiento para la preparacion de 1-(3-halo-2-piridinil)piperazinas. | |
| ES2000170A6 (es) | Procedimiento para preparar 5,11-dihidro-6h-pirido(2,3-b)(1,4)-benzodiazepin-6-onas substituidas en posicion 11 | |
| FI811682L (fi) | Lh-rh antagonister | |
| ES2084627T3 (es) | Antagonistas de neuroquinina ciclica. | |
| DD128973A1 (de) | Verfahren zur herstellung von peptiden,die tyrosinsulfat enthalten | |
| Clottes | European Palaeolithic rock art and spatial structures |